Marks Group Wealth Management Inc increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 1.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,752 shares of the company’s stock after buying an additional 367 shares during the quarter. Marks Group Wealth Management Inc’s holdings in Zoetis were worth $5,358,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Meridian Wealth Partners LLC purchased a new position in Zoetis in the first quarter valued at about $26,000. Sound Income Strategies LLC grew its stake in Zoetis by 1,069.2% in the second quarter. Sound Income Strategies LLC now owns 152 shares of the company’s stock valued at $28,000 after purchasing an additional 139 shares in the last quarter. Lakeview Capital Partners LLC purchased a new position in Zoetis in the first quarter valued at about $30,000. Accel Wealth Management grew its stake in Zoetis by 97.0% in the first quarter. Accel Wealth Management now owns 197 shares of the company’s stock valued at $31,000 after purchasing an additional 97 shares in the last quarter. Finally, WealthShield Partners LLC grew its stake in Zoetis by 60.2% in the second quarter. WealthShield Partners LLC now owns 165 shares of the company’s stock valued at $31,000 after purchasing an additional 62 shares in the last quarter. Hedge funds and other institutional investors own 89.53% of the company’s stock.
A number of analysts have weighed in on the company. Barclays boosted their price target on Zoetis from $208.00 to $235.00 and gave the stock an “overweight” rating in a research report on Friday, August 6th. Argus boosted their price target on Zoetis from $195.00 to $225.00 and gave the stock a “buy” rating in a research report on Wednesday, August 25th. Raymond James cut Zoetis from an “outperform” rating to a “market perform” rating in a research report on Friday, July 16th. Cantor Fitzgerald boosted their price objective on Zoetis from $210.00 to $238.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 13th. Finally, Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $186.00 price objective for the company in a research report on Tuesday, June 1st. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $199.08.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 5th. The company reported $1.19 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.11. Zoetis had a return on equity of 53.87% and a net margin of 25.76%. During the same period in the prior year, the company posted $0.89 EPS. As a group, sell-side analysts forecast that Zoetis Inc. will post 4.53 EPS for the current fiscal year.
In related news, EVP Roxanne Lagano sold 22,450 shares of the firm’s stock in a transaction on Thursday, July 22nd. The stock was sold at an average price of $199.18, for a total transaction of $4,471,591.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Kristin C. Peck sold 14,500 shares of the firm’s stock in a transaction on Wednesday, August 25th. The stock was sold at an average price of $203.55, for a total value of $2,951,475.00. Following the sale, the chief executive officer now directly owns 43,424 shares in the company, valued at approximately $8,838,955.20. The disclosure for this sale can be found here. In the last three months, insiders sold 48,003 shares of company stock worth $9,711,854. 0.17% of the stock is currently owned by company insiders.
Zoetis, Inc discovers, develops, and manufactures a portfolio of animal health medicines and vaccines. The firm operates through the following segments: United States &International. Its products are complemented by diagnostic products, genetic tests, bio devices, and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal.
Read More: What can cause a stock to outperform?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.